Neural Interface Biocompatible Materials Patent Landscape
The neural interface biocompatible materials field is in a growth phase, with the field still expanding on a multi-year basis even as annual volume has eased from its 2022 peak; NeuronexusTechnologies holds the leading position, and the top five filers collectively account for nearly half of all activity among the hundred largest filers. The United States dominates jurisdictional filings, and a wave of new entrants — including Precision Neuroscience and several university–industry pairs — signals that competitive intensity is rising.
NeuronexusTechnologies leads a moderately concentrated field with active academic challengers
NeuronexusTechnologies Inc ranks first with 12 patent records, followed by Precision Neuroscience Corp with 8 and Luna Labs USA LLC with 6, establishing a clear three-tier hierarchy at the top of the applicant ranking.
The top five filers — NeuronexusTechnologies, Precision Neuroscience, Luna Labs USA, Revision Implant NV, and Beijing BCIFlex Medical Tech — collectively hold 47% of the combined total among the hundred largest filers, indicating moderate concentration: a dominant leader exists but challengers are not far behind, and the field is not monopolized.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | NeuronexusTechnologies Inc | 12 | |
| 2 | Precision Neuroscience Corp | 8 | |
| 3 | Luna Labs USA LLC | 6 | |
| 4 | Revision Implant NV | 5 | |
| 5 | Beijing BCIFlex Medical Tech Co Ltd | 4 | |
| 6 | Cortec GmbH | 4 | |
| 7 | University of Basel, Vice-Rectorate Research | 3 | |
| 8 | William Marsh Rice University | 3 | |
| 9 | Carnegie Mellon University | 2 | |
| 10 | Shanghai Jiao Tong University | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Wisconsin Alumni Research Foundation | 2 | |
| 12 | Ningbo Digital Twin (Eastern Institute of Technology) Research Institute | 2 | |
| 13 | Board of Regents, The University of Texas System | 2 | |
| 14 | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION | 2 | |
| 15 | University of Pittsburgh | 2 | |
| 16 | Wuhan Neuracom Technology Development Co Ltd | 2 | |
| 17 | Arizona Board of Regents, University of Arizona | 2 | |
| 18 | Hangzhou Dianzi University Wenzhou Research Institute Co Ltd | 1 | |
| 19 | Luna Innovations Inc | 1 | |
| 20 | Craig Stanley R Jr | 1 |
NeuronexusTechnologies’ position across electrotherapy, diagnostic surgery, and photolithography classes suggests it is pursuing a vertically integrated materials-to-device strategy, while challengers cluster in the core electrotherapy and surgical diagnosis classes, pointing to competitive pressure on the central use cases.
Filings from the most recent 18–24 months are subject to publication lag and will be undercounted until applications complete examination; the 2025–2026 figures should be read as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year growth holds despite a post-2022 moderation in annual volume
Two signals define the current state of the field: a filing trend that has expanded materially over the past decade but eased from a 2022 spike, and a technology composition heavily anchored in electrotherapy and surgical diagnosis with several adjacent branches remaining sparsely covered.
Annual filing trend
Annual filings grew from 4 records in 2017 to a peak of 10 in 2022 before settling into the 6–7 range through 2025; the recent three-year window still sits well above the prior three-year window (+53%), confirming multi-year growth even as the 2022 peak has not been retested. The 2025 and 2026 bars will grow as publications clear the examination pipeline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (electrotherapy and radiation therapy) and A61B (diagnosis and surgery) dominate the IPC composition, together accounting for the substantial majority of classified records. Downstream material-fabrication classes — G03F (photolithography), A61M (devices for body fluids), A61F (implants and prostheses), and H01B (conductors and insulators) — each carry single-digit record counts, indicating that materials-processing and structural-integration pathways remain sparsely patented relative to the end-use device classes.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Conformable neural interface device with hydrogel …
Disclosed are highly compliant bioelectronic neural interface devices with hydrogel adhesion. Example devices include adhesion-promoting functional groups that facilitate enhanced electrical contact with the nerve without the need for continuous application of pressure. A transfer process may be used to fabricate the device using a sacrificial material… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Neural interface assembly and method for making an… | 107 |
| 2 | Neural Interface Assembly and Method For Making an… | 68 |
| 3 | An RFID-based apparatus, system, and method for th… | 64 |
| 4 | Liquid crystal polymer-based electrode array and p… | 46 |
| 5 | Visual prosthesis employing virtual neural electro… | 43 |
| 6 | Neural electrode system with a carrier having a ta… | 32 |
| 7 | Omnidirectional deployable multichannel neural ele… | 19 |
| 8 | Electrode Placement System for Penetrating Neural … | 18 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for materials R&D investment decisions
The field’s growth trajectory, moderate concentration, emerging academic–industry collaborations, and US-centric jurisdictional profile each carry distinct implications for where new entrants and incumbents should direct R&D resources.
Growth stage with eased annual pace — window still opening
The field carries a Growth lifecycle designation: the recent three-year filing window is 53% above the prior three-year window, confirming genuine expansion. Annual volume has eased from its 2022 peak rather than continuing to accelerate, which suggests the field is maturing beyond early-stage opportunism but has not yet plateaued. New entrants arriving now will face a more populated competitive map than pioneers did in 2017–2019, but white space in adjacent fabrication and conductor classes remains accessible.
Growth · post-2022 peakModerate concentration — a clear leader but a crowded second tier
NeuronexusTechnologies holds a 2:1 record advantage over its nearest rival, Precision Neuroscience, which is meaningful but not prohibitive. The top five filers hold 47% of activity among the hundred largest filers, leaving more than half of that activity distributed across a long tail of universities, startups, and regional players. Challengers that can differentiate on materials chemistry or fabrication process — rather than competing directly in the core electrotherapy device class — face a lower barrier to establishing a defensible position.
Moderate concentrationUniversity–industry pairing is the dominant collaboration model
The most active co-filing pair in the corpus is the University of Freiburg (Albert-Ludwigs-Universitat Freiburg) with Cortec GmbH, sharing 4 joint records — the strongest collaboration signal in the dataset. William Marsh Rice University and the Board of Regents of the University of Texas System share 2 joint records, a second university-to-university pairing with regional proximity. These patterns suggest that materials-science expertise residing in European and US research universities is being commercialized through close industry partnerships rather than internal corporate R&D alone.
Academic–industry co-filingUS-centric filings; Europe and China are secondary but active
The United States accounts for 37 patent records, making it the dominant filing jurisdiction by a wide margin. Europe (EPO) registers 13 records and China 11, with WIPO (PCT) adding 7 records that signal applicants seeking multi-jurisdiction coverage. India appears with a single record. For a company seeking freedom-to-operate, a US-first filing strategy appears consistent with where the bulk of current activity is concentrated, though the Chinese and European pipelines are material enough to warrant monitoring.
US-led · Europe & China secondaryGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Albert-Ludwigs-Universitat Freiburg (University of Freiburg) | Cortec GmbH | 4 |
| William Marsh Rice University | Board of Regents, The University of Texas System | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
NeuronexusTechnologies leads on breadth; Precision Neuroscience is the most active new entrant
The two front-runners differ sharply in trajectory: NeuronexusTechnologies holds the largest accumulated position across multiple technology classes, while Precision Neuroscience has arrived as a new entrant with strong recent momentum concentrated in the core device classes.
NeuronexusTechnologies Inc
NeuronexusTechnologies holds 12 patent records — the largest position in the corpus — and is the only applicant with meaningful coverage across A61N (electrotherapy), A61B (surgical diagnosis), and G03F (photolithography/microfabrication), suggesting a strategy that spans from materials patterning through to the finished neural electrode device. Its photolithography footprint in particular is distinctive and creates a fabrication-process moat that other applicants have not replicated at scale.
patent records: 12Precision Neuroscience Corp
Precision Neuroscience Corp holds 8 patent records and carries a ‘new entrant’ trajectory designation — all of its recent records were filed in the recent measurement window, indicating a concentrated and rapid build-out of its IP position rather than a long-accumulated portfolio. Its technology emphasis is split evenly between A61B (diagnostic and surgical applications) and A61N (electrotherapy), aligning it directly with the field’s dominant use-case classes and placing it on a collision course with NeuronexusTechnologies in the core electrode-interface space.
patent records: 8| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Revision Implant NV | 4 | ▲ new entrant |
| Cortec GmbH | 2 | ▲ new entrant |
| Beijing BCIFlex Medical Tech Co Ltd | 3 | ▲ new entrant |
| Precision Neuroscience Corp | 4 | ▲ new entrant |
| William Marsh Rice University | 3 | ▲ new entrant |
Fabrication processes and conductor materials are under-served relative to device-level classes
While A61N and A61B dominate the corpus, several adjacent IPC branches remain sparsely populated; these represent observations of relative sparsity that may carry technical value for applicants willing to patent further upstream in the materials and manufacturing stack.
H01B · Cables, Conductors & Insulators
With only 3 patent records and a 2% share among classified records, H01B is among the sparsest branches in the corpus. Conductor and insulator materials are central to the long-term stability and biocompatibility of implanted neural interfaces — chronic foreign-body response is often driven by the mechanical and chemical properties of interconnect materials — yet this branch is almost unpatented in the current landscape. An applicant focusing on novel conductive polymers, carbon-nanotube composites, or bioresorbable conductors for chronic implants could establish a differentiated position with relatively few filings.
Search this in Eureka →A61L · Sterilising, Disinfecting & Antimicrobial Coatings
A61L holds only 2 patent records, representing a 1% share of classified records — the lowest share among the identified adjacent branches. Surface sterilization and antimicrobial coating chemistries are practically necessary for any implantable neural device, making this sparsity notable. An applicant with expertise in bioactive surface coatings, hydrogel anti-fouling layers, or zwitterionic polymer grafting for neural substrates could address a gap that sits at the intersection of materials science and infection control. Entry would benefit from pairing with an existing device-class applicant given the collaboration patterns already evident in the corpus.
Search this in Eureka →How leading applicants differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61N 1 · Electrotherapy & radiation therapy | A61B 5 · Diagnosis & surgery | A61M 25 · Devices for body fluids | G03F 7 · Photolithography & photomechanics | A61F 2 · Implants & prostheses |
|---|---|---|---|---|---|
| NeuronexusTechnologies Inc | Strong · 12 | Strong · 11 | Moderate · 6 | Strong · 7 | Absent |
| Precision Neuroscience Corp | Strong · 4 | Strong · 4 | Absent | Absent | Absent |
| Luna Innovations Inc | Strong · 4 | Strong · 4 | Absent | Absent | Absent |
| Cortec GmbH | Strong · 4 | Strong · 4 | Absent | Absent | Absent |
| Precision Neurotech LLC | Strong · 4 | Strong · 3 | Absent | Absent | Absent |
| Beijing BCIFlex Medical Tech Co Ltd | Strong · 4 | Moderate · 2 | Absent | Absent | Absent |
Frequently asked questions
The corpus covers 52 patent families. The applicant ranking is expressed in patent records, which can exceed the family count because a single family may be filed across multiple jurisdictions and counted separately at each.
NeuronexusTechnologies Inc leads with 12 patent records, ahead of Precision Neuroscience Corp at 8 and Luna Labs USA LLC at 6. The top five applicants together account for 47% of the activity among the hundred largest filers.
Yes, on a multi-year basis. The recent three-year filing window is 53% above the prior three-year window, placing the field in a Growth lifecycle stage. Annual volume has eased from its 2022 peak of 10 records, and the most recent years (2024–2025) are further understated by publication lag.
The United States leads with 37 patent records, followed by Europe (EPO) with 13 and China with 11. WIPO (PCT) accounts for 7 records, indicating some applicants are pursuing broad multi-jurisdiction protection. India has 1 record.
Yes. The strongest co-filing relationship is between the University of Freiburg (Albert-Ludwigs-Universitat Freiburg) and Cortec GmbH, with 4 joint records. William Marsh Rice University and the Board of Regents of the University of Texas System share 2 joint records. Both pairs follow a university–industry or university–university model, consistent with the field’s reliance on academic materials science expertise.
The most-cited work in the corpus is titled ‘Neural interface assembly and method for making an…’ with 107 citations, followed by a closely related record at 68 citations. A record on an RFID-based apparatus for neural applications ranks third at 64 citations, and a liquid crystal polymer-based electrode array patent has 46 citations — indicating that foundational assembly and electrode-substrate materials patents are the most referenced prior art in this domain.
Ready to map your own neural interface materials landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.